GlassScriptPhysician profile
Adam M Miller
NPI 1164697835
$1,717.77
in general payments reported to CMS, 2019-2025
20 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.47 · 2022: $220 · 2023: $208 · 2024: $405 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $332.26 | 2022-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Depuy Synthes Sales INC. | $175.38 | 2024-2025 | Na |
| Abbvie INC. | $168.85 | 2022-2025 | |
| Oyster Point Pharma, INC. | $158.86 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $131.28 | 2025 | |
| Thea Pharma INC. | $108.84 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $101.67 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $97.40 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $69.63 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $61.06 | 2022-2025 | Dextenza |
| Astellas Pharma US INC | $53.72 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $52.90 | 2021-2023 | |
| Dompe US, INC. | $41.01 | 2022-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $38.37 | 2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $28.07 | 2022-2023 | Flarex |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $24.54 | 2023 | |
| Kala Pharmaceuticals, INC. | $23.15 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.85 | 2021 | |
| Harrow Eye, LLC | $17.45 | 2025 | Vevye |
| Next Science LLC | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.